Episode
Episode 65. Circulating Tumor DNA in DLBCL with Dr. Ash Alizadeh and Dr. David Russler-Germain
- Podcast
- Blood Cancer Talks
- Published
- Sep 24, 2025
- Duration seconds
- 3188
- Processing state
not_requested- Canonical source
- https://share.transistor.fm/s/3df6104c
Actions
POST https://stenobird.com/v1/public/podcasts/blood-cancer-talks-5570002/episodes/episode-65-circulating-tumor-dna-in-dlbcl-with-dr-ash-alizadeh-and-dr-david-russler-germain/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/blood-cancer-talks-5570002/episode-65-circulating-tumor-dna-in-dlbcl-with-dr-ash-alizadeh-and-dr-david-russler-germain.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
In this episode of Blood Cancer Talks, hosts Eddie, Ashwin, and Raj welcome two distinguished experts to explore the cutting-edge field of circulating tumor DNA (ctDNA) in B-cell lymphomas. Dr. David Russler-Germain, a lymphoma clinician from Siteman Cancer Centre at Washington University in St. Louis, returns as a familiar voice to the podcast audience. Joining him is Dr. Ash Alizadeh, the Moghadam Family Professor of Medicine, Oncology, and Hematology at Stanford University and leader of the Cancer Genomics Program at Stanford Cancer Institute. Dr. Alizadeh has been instrumental in advancing our understanding of lymphomagenesis and lymphoma genetics over the past two decades, pioneering multiple ctDNA techniques that are revolutionizing cancer care. Together, they discuss the transformative potential of ctDNA technology in B-cell lymphomas, particularly DLBCL, covering everything from the technical evolution of biomarker detection to groundbreaking clinical data that may reshape how we monitor and treat these aggressive cancers. Key Discussion Topics 1. Genetic Heterogeneity in B-Cell Lymphomas Complex genetic landscape of DLBCL Implications for treatment strategies Need for personalized approaches 2. Clinical Need for ctDNA in Lymphoma Why ctDNA is needed in aggressive lymphomas: Curative vs. non-curative treatment settings Limitations of current PET imaging Additional prognostic information beyond imaging Risk stratification capabilities Potential to avoid overtreatment Therapy adaptation opportunities 3. Challenges in Lymphoma MRD Assessment Why lymphoma MRD is more complex than other hematologic malignancies: Differences from acute leukemias, CLL, and myeloma Technical challenges specific to lymphoid tumors Lower circulating tumor burden compared to liquid tumors…